EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In-label, off-label prescription, efficacy and tolerability of dalbavancin: report from a National Registry

Silvano Esposito, Pasquale Pagliano, Giuseppe De Simone, Amedeo Guarino, Angelo Pan, Paola Brambilla, Claudio Mastroianni, Miriam Lichtner, Pierluigi Brugnaro, Anna Carretta, Teresa Santantonio, Gaetano Brindicci und 12 weitere

Infection · 2024-08 · 52 (4) · 1297-1306

DOI: 10.1007/s15010-024-02176-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Infection, online erschienen am 07.02.2024. Verfasst von Silvano Esposito und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, University of Salerno, Salerno, Italy. silvanoesposito@libero.it. Hauptthemen laut MEDLINE: Teicoplanin, Anti-Bacterial Agents, Off-Label Use, Registries. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Salerno.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Although dalbavancin is currently approved for the treatment of ABSSIs, several studies suggest its efficacy and tolerance as long-term therapy for other off-label indications requiring prolonged intravenous antibiotic administration.

Methods

We conducted a prospective nationwide study of dalbavancin use in real-life settings for both approved and off-label indications analysing for each case the clinical and microbiological characteristics of infection the efficacy and safety of treatments.

Results

During the study period (from December 2018 to July 2021), the ID specialists from 14 different centres enrolled 223 patients treated with dalbavancin [141 males (63%) and 82 females (37%); male/female ratio 1.72; mean age 59 (SD 17.2) years, (range 15–96). Most patients in the study population (136/223; 61.0%) came from community rather than health care facilities and most of them were visited in Infectious Diseases wards (93/223; 41.7%) and clinics (55/223; 24.7%) even though some patients were cured in other settings, such as surgery wards (18/223; 8.1%), orthopaedic wards (11/223; 4.9%), Emergency Rooms (7/223; 3.1%) and non-surgical other than ID wards (6/223; 2.7%). The most common ID diagnoses were osteomyelitis (44 cases/223; 19.7%; of which 29 acute and 15 chronic osteomyelitis), cellulitis (28/223; 12.5%), cutaneous abscess (23/223; 10.3%), orthopaedic prosthesis-associated infection (22/223; 9.9%), surgical site infection (20/223; 9.0%) and septic arthritis (15/223; 6.7%).

Conclusion

In conclusion, by virtue of its PK/PD properties, dalbavancin represents a valuable option to daily in-hospital intravenous or outpatient antimicrobial regimens also for off-label indications requiring a long-term treatment of Gram-positive infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TeicoplaninAnti-Bacterial AgentsOff-Label UseRegistriesHumansMiddle AgedMaleFemaleAdultAgedAdolescentAged, 80 and overYoung AdultProspective StudiesTreatment Outcome

Stichwörter der Autor:innen

DalbavancinIn-labelOff-label

Substanzen

dalbavancinTeicoplaninAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Infectious Diseases, University of Salerno, Salerno, Italy. silvanoesposito@libero.it.
  • Department of Infectious Diseases, University of Salerno, Salerno, Italy.
  • Department of Public Health, University of Naples Federico II, Naples, Italy.
  • Department of Infectious Diseases, Istituti Ospitalieri of Cremona, Cremona, Italy.
  • Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy.
  • Department of Public Health and Infectious Diseases, Sapienza University, Latina, Italy.

Förderung

  • Università degli Studi di Salerno

Zitieren

APA

Esposito, S., Pagliano, P., De Simone, G., Guarino, A., Pan, A., Brambilla, P., Mastroianni, C., Lichtner, M., Brugnaro, P., Carretta, A., Santantonio, T., Brindicci, G., Carrega, G., Montagnani, F., Lapadula, G., Spolti, A., Luzzati, R., Schiaroli, E., Scaglione, V., …, & Italian Society of Infectious, Tropical Diseases (2024). In-label, off-label prescription, efficacy and tolerability of dalbavancin: report from a National Registry. Infection, 52(4), 1297-1306. https://doi.org/10.1007/s15010-024-02176-2

Vancouver

Esposito S, Pagliano P, De Simone G, Guarino A, Pan A, Brambilla P, et al. In-label, off-label prescription, efficacy and tolerability of dalbavancin: report from a National Registry. Infection. 2024;52(4):1297-1306. doi:10.1007/s15010-024-02176-2

BibTeX
@article{Esposito2024,
  author = {Esposito, Silvano and Pagliano, Pasquale and De Simone, Giuseppe and Guarino, Amedeo and Pan, Angelo and Brambilla, Paola and Mastroianni, Claudio and Lichtner, Miriam and Brugnaro, Pierluigi and Carretta, Anna and Santantonio, Teresa and Brindicci, Gaetano and Carrega, Giuliana and Montagnani, Francesca and Lapadula, Giuseppe and Spolti, Anna and Luzzati, Roberto and Schiaroli, Elisabetta and Scaglione, Vittoria and Pallotto, Carlo and Tacconi, Danilo and Quintieri, Francesco and Trecarichi, Enrico and Italian Society of Infectious, Tropical Diseases, Italian Society of Infectious, Tropical Diseases},
  title = {In-label, off-label prescription, efficacy and tolerability of dalbavancin: report from a National Registry},
  journal = {Infection},
  year = {2024},
  volume = {52},
  number = {4},
  pages = {1297--1306},
  doi = {10.1007/s15010-024-02176-2}
}
Kostenlos starten →